Should I buy or sell Aytu BioPharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aytu BioPharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AYTU shares. View AYTU analyst ratings or view top-rated stocks .

What is Aytu BioPharma's stock price target for 2024?

2 brokers have issued 12-month price objectives for Aytu BioPharma's stock. Their AYTU share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 111.9% from the stock's current price. View analysts price targets for AYTU or view top-rated stocks among Wall Street analysts .

How have AYTU shares performed in 2023?

Aytu BioPharma's stock was trading at $0.1890 at the start of the year. Since then, AYTU stock has increased by 1,148.7% and is now trading at $2.36. View the best growth stocks for 2023 here .

When is Aytu BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024. View our AYTU earnings forecast .

How were Aytu BioPharma's earnings last quarter?

Aytu BioPharma, Inc. (NASDAQ:AYTU) issued its earnings results on Wednesday, September, 27th. The company reported $0.16 EPS for the quarter. The business earned $30.73 million during the quarter. Aytu BioPharma had a negative trailing twelve-month return on equity of 47.43% and a negative net margin of 24.03%.

When did Aytu BioPharma's stock split?

Aytu BioPharma shares reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aytu BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioPharma investors own include Sorrento Therapeutics (SRNE) , Vaxart (VXRT) , ADMA Biologics (ADMA) , Heat Biologics (HTBX) , Inovio Pharmaceuticals (INO) , VBI Vaccines (VBIV) , iBio (IBIO) , Matinas BioPharma (MTNB) , Bionano Genomics (BNGO) and SCYNEXIS (SCYX) .

Who are Aytu BioPharma's major shareholders?

Aytu BioPharma's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armistice Capital, Llc, Greg Pyszczymuka and Joshua R Disbrow. View institutional ownership trends .

How do I buy shares of Aytu BioPharma?

Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Aytu BioPharma Stock Price, News & Analysis (NASDAQ:AYTU)

$2.36

-0.16 (-6.35%)

(As of 11/28/2023 ET)

Compare

Today's Range: $2.29
▼
$2.54
50-Day Range: $1.55
▼
$3.33
52-Week Range: $1.38
▼
$4.88

Volume: 35,229 shs
Average Volume: 50,112 shs
Market Capitalization: $13.15 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Aytu BioPharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 111.9% Upside
$5.00 Price Target
Short Interest: Healthy
11.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.45
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

405th out of 949 stocks

Pharmaceutical Preparations Industry

185th out of 444 stocks

3.5

Analyst's Opinion

Consensus Rating
Aytu BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Aytu BioPharma has a forecasted upside of 111.9% from its current price of $2.36.
Amount of Analyst Coverage
Aytu BioPharma has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
11.25% of the float of Aytu BioPharma has been sold short.
Short Interest Ratio / Days to Cover
Aytu BioPharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aytu BioPharma has recently decreased by 4.71%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Aytu BioPharma does not currently pay a dividend.
Dividend Growth
Aytu BioPharma does not have a long track record of dividend growth.

3.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Aytu BioPharma has received a 39.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Carbinoxamine", "Methylphenidate", and "Amphetamine" products. See details.
Environmental Sustainability
The Environmental Impact score for Aytu BioPharma is -2.45.

2.7

News and Social Media Coverage

News Sentiment
Aytu BioPharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Aytu BioPharma this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Aytu BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aytu BioPharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.34% of the stock of Aytu BioPharma is held by insiders.
Percentage Held by Institutions
45.09% of the stock of Aytu BioPharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Aytu BioPharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aytu BioPharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aytu BioPharma has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aytu BioPharma Stock (NASDAQ:AYTU)

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.

AYTU Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AYTU Stock News Headlines

November 15, 2023 | finance.yahoo.com

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript

November 14, 2023 | finanznachrichten.de

Aytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results

November 29, 2023 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

November 14, 2023 | finance.yahoo.com

Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results

November 13, 2023 | markets.businessinsider.com

Aytu BioPharma earnings: here's what to expect

November 8, 2023 | finance.yahoo.com

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year

November 7, 2023 | finance.yahoo.com

Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

October 28, 2023 | finanznachrichten.de

Aytu BioPharma, Inc.: Aytu BioPharma Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement

November 29, 2023 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

October 28, 2023 | markets.businessinsider.com

Aytu BioPharma: Strategic Manufacturing Transition and Financial Growth Bolster Buy Rating

October 26, 2023 | finance.yahoo.com

Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

October 9, 2023 | finance.yahoo.com

Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023

September 28, 2023 | finance.yahoo.com

There's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted Revenues

September 28, 2023 | finance.yahoo.com

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2023 Earnings Call Transcript

September 27, 2023 | finance.yahoo.com

Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023

September 26, 2023 | benzinga.com

Earnings Outlook For Aytu BioPharma

September 26, 2023 | markets.businessinsider.com

Aytu BioPharma earnings: here's what Wall Street expects

September 22, 2023 | finance.yahoo.com

Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023

September 13, 2023 | finanznachrichten.de

Aytu BioPharma, Inc.: Aytu BioPharma to Present at LD Micro Main Event XVI Conference

September 13, 2023 | finance.yahoo.com

Aytu BioPharma to Present at LD Micro Main Event XVI Conference

August 9, 2023 | msn.com

Maxim Group Initiates Coverage of Aytu BioPharma (AYTU) with Buy Recommendation

August 9, 2023 | finance.yahoo.com

Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Expected To Breakeven In The Medium-Term

July 31, 2023 | finance.yahoo.com

Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority

July 6, 2023 | msn.com

Aytu BioPharma (AYTU) Price Target Increased by 71.43% to 122.40

June 14, 2023 | finanznachrichten.de

Aytu BioPharma, Inc.: Aytu to Participate in the Maxim Group Virtual Healthcare Conference

June 13, 2023 | finanznachrichten.de

Aytu BioPharma, Inc.: Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market

June 13, 2023 | finance.yahoo.com

Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market

See More Headlines

Receive AYTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 9/27/2023
Today: 11/29/2023
Next Earnings (Estimated): 2/20/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AYTU
CUSIP: N/A
CIK: 1385818
Web: aytubio.com
Phone: (720) 437-6580
Fax: N/A
Employees: 150
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +111.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,050,000.00
Net Margins: -24.03%
Pretax Margin: -24.03%
Return on Equity: -47.43%
Return on Assets: -13.45%

Debt

Debt-to-Equity Ratio: 0.46
Current Ratio: 1.08
Quick Ratio: 0.88

Sales & Book Value

Annual Sales: $107.40 million
Price / Sales: 0.12
Cash Flow: $0.93 per share
Price / Cash Flow: 2.55
Book Value: $5.78 per share
Price / Book: 0.41

Miscellaneous

Outstanding Shares: 5,570,000
Free Float: 5,326,000
Market Cap: $13.15 million
Optionable: Not Optionable
Beta: -0.86

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Joshua R. Disbrow (Age 48)
Chairman & CEO
Comp: $708k
Mr. Mark K. Oki CPA (Age 54)
CFO, Secretary & Treasurer
Comp: $522.84k
Mr. Greg Pyszczymuka (Age 44)
Chief Commercial Officer
Comp: $525k
Ms. Victoria Cordova
Vice President of People & Culture
Mr. Jarrett T. Disbrow Ph.D. (Age 48)
Chief Business Officer & President of Consumer Health
Comp: $355k
Mr. Russ McMahen
Senior Vice President of Research & Development
Mr. Ryan J. Selhorn CPA (Age 41)
Executive VP of Finance & Business Optimization

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

AYTU Stock Analysis - Frequently Asked Questions

Should I buy or sell Aytu BioPharma stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aytu BioPharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AYTU shares.
View AYTU analyst ratings or view top-rated stocks.
What is Aytu BioPharma's stock price target for 2024?: 2 brokers have issued 12-month price objectives for Aytu BioPharma's stock. Their AYTU share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 111.9% from the stock's current price.
View analysts price targets for AYTU or view top-rated stocks among Wall Street analysts.
How have AYTU shares performed in 2023?: Aytu BioPharma's stock was trading at $0.1890 at the start of the year. Since then, AYTU stock has increased by 1,148.7% and is now trading at $2.36.
View the best growth stocks for 2023 here.
When is Aytu BioPharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our AYTU earnings forecast.
How were Aytu BioPharma's earnings last quarter?: Aytu BioPharma, Inc. (NASDAQ:AYTU) issued its earnings results on Wednesday, September, 27th. The company reported $0.16 EPS for the quarter. The business earned $30.73 million during the quarter. Aytu BioPharma had a negative trailing twelve-month return on equity of 47.43% and a negative net margin of 24.03%.

When did Aytu BioPharma's stock split?: Aytu BioPharma shares reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Aytu BioPharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioPharma investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), iBio (IBIO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and SCYNEXIS (SCYX).
Who are Aytu BioPharma's major shareholders?: Aytu BioPharma's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armistice Capital, Llc, Greg Pyszczymuka and Joshua R Disbrow.
View institutional ownership trends.
How do I buy shares of Aytu BioPharma?: Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AYTU) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial